Amer M Zeidan1,2, Rong Wang2,3, Amy J Davidoff2,4, Shuangge Ma5, Yinjun Zhao5, Steven D Gore1, Cary P Gross1,2, Xiaomei Ma2,3. 1. Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut. 2. Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, Connecticut. 3. Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut. 4. Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut. 5. Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut.
Abstract
BACKGROUND: Although newer treatments for myelodysplastic syndromes (MDS), particularly hypomethylating agents (HMAs), are expensive, it is unclear whether MDS-related costs of care are associated with overall survival. This study evaluated the relation between MDS-related costs and survival among Medicare beneficiaries with MDS. METHODS: Eligible patients were identified from the Surveillance, Epidemiology, and End Results-Medicare database with codes for MDS from International Classification of Diseases for Oncology, 3rd edition. The patients were diagnosed between January 1, 2005 and December 31, 2011, were 66 years old or older, and were followed through death or the end of study (December 31, 2012). Medicare payments were used to estimate costs. Cumulative costs in a propensity score-matched group of cancer-free Medicare beneficiaries were subtracted from costs in the MDS cohort in each registry to estimate MDS-related costs. Hazard ratios (HRs) and 95% confidence intervals (CIs) were derived from multivariate Cox proportional hazards models adjusted for patient and disease characteristics. RESULTS: There were 8580 eligible patients, and 1,267 (14.7%) received HMAs. The overall 2-year survival rate was 48.7%, and the 2-year registry-specific MDS-related cost per patient ranged from $40,793 to $78,156 across 16 registries. The 2-year MDS-related cost was not associated with survival in the overall study population (first tertile, reference; second tertile, HR, 0.96; 95% CI, 0.89-1.04; P = .29; third tertile, HR, 0.98; 95% CI, 0.91-1.06; P = .64) or in subgroups of patients who did or did not receive HMAs. CONCLUSIONS: Medicare expenditures for elderly patients with MDS varied across registries but were not associated with survival. A lack of an association between costs and outcomes warrants additional research because it may help to identify potential areas for cost-saving interventions without compromising patient outcomes. Cancer 2016;122:1598-607.
BACKGROUND: Although newer treatments for myelodysplastic syndromes (MDS), particularly hypomethylating agents (HMAs), are expensive, it is unclear whether MDS-related costs of care are associated with overall survival. This study evaluated the relation between MDS-related costs and survival among Medicare beneficiaries with MDS. METHODS: Eligible patients were identified from the Surveillance, Epidemiology, and End Results-Medicare database with codes for MDS from International Classification of Diseases for Oncology, 3rd edition. The patients were diagnosed between January 1, 2005 and December 31, 2011, were 66 years old or older, and were followed through death or the end of study (December 31, 2012). Medicare payments were used to estimate costs. Cumulative costs in a propensity score-matched group of cancer-free Medicare beneficiaries were subtracted from costs in the MDS cohort in each registry to estimate MDS-related costs. Hazard ratios (HRs) and 95% confidence intervals (CIs) were derived from multivariate Cox proportional hazards models adjusted for patient and disease characteristics. RESULTS: There were 8580 eligible patients, and 1,267 (14.7%) received HMAs. The overall 2-year survival rate was 48.7%, and the 2-year registry-specific MDS-related cost per patient ranged from $40,793 to $78,156 across 16 registries. The 2-year MDS-related cost was not associated with survival in the overall study population (first tertile, reference; second tertile, HR, 0.96; 95% CI, 0.89-1.04; P = .29; third tertile, HR, 0.98; 95% CI, 0.91-1.06; P = .64) or in subgroups of patients who did or did not receive HMAs. CONCLUSIONS: Medicare expenditures for elderly patients with MDS varied across registries but were not associated with survival. A lack of an association between costs and outcomes warrants additional research because it may help to identify potential areas for cost-saving interventions without compromising patient outcomes. Cancer 2016;122:1598-607.
Authors: Amy J Davidoff; Ilene H Zuckerman; Naimish Pandya; Franklin Hendrick; Xuehua Ke; Arti Hurria; Stuart M Lichtman; Arif Hussain; Jonathan P Weiner; Martin J Edelman Journal: J Geriatr Oncol Date: 2013-04 Impact factor: 3.599
Authors: Elliott S Fisher; David E Wennberg; Thérèse A Stukel; Daniel J Gottlieb; F L Lucas; Etoile L Pinder Journal: Ann Intern Med Date: 2003-02-18 Impact factor: 25.391
Authors: Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland Journal: J Clin Oncol Date: 2002-05-15 Impact factor: 44.544
Authors: Joan L Warren; Martin L Brown; Michael P Fay; Nicola Schussler; Arnold L Potosky; Gerald F Riley Journal: J Clin Oncol Date: 2002-01-01 Impact factor: 44.544
Authors: Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman Journal: Lancet Oncol Date: 2009-02-21 Impact factor: 41.316
Authors: Mary Beth Landrum; Ellen R Meara; Amitabh Chandra; Edward Guadagnoli; Nancy L Keating Journal: Health Aff (Millwood) Date: 2008 Jan-Feb Impact factor: 6.301
Authors: Amy J Davidoff; Xin Hu; Jan Philipp Bewersdorf; Rong Wang; Nikolai A Podoltsev; Scott F Huntington; Steven D Gore; Xiaomei Ma; Amer M Zeidan Journal: Leuk Lymphoma Date: 2019-12-26
Authors: Sara Tannenbaum; Pamela R Soulos; Jeph Herrin; Sarah Mougalian; Jessica B Long; Rong Wang; Xiaomei Ma; Cary P Gross; Xiao Xu Journal: Med Care Date: 2017-12 Impact factor: 2.983
Authors: Lisa Pleyer; Hartmut Döhner; Hervé Dombret; John F Seymour; Andre C Schuh; C L Beach; Arlene S Swern; Sonja Burgstaller; Reinhard Stauder; Michael Girschikofsky; Heinz Sill; Konstantin Schlick; Josef Thaler; Britta Halter; Sigrid Machherndl Spandl; Armin Zebisch; Angelika Pichler; Michael Pfeilstöcker; Eva M Autzinger; Alois Lang; Klaus Geissler; Daniela Voskova; Wolfgang R Sperr; Sabine Hojas; Inga M Rogulj; Johannes Andel; Richard Greil Journal: Int J Mol Sci Date: 2017-02-15 Impact factor: 5.923